CHANGES IN PLATINUM FREE-INTERVAL ACROSS OVARIAN CANCER LINES OF TREATMENT: OCEANIA REAL-WORLD STUDY- BRAZIL

Introduction: Disease recurrence is common in patients with ovarian cancer (OC), with many requiring multiple lines of therapy (LOTs). Platinum-based therapy remains the cornerstone of treatment for platinum-sensitive patients. The platinum-free interval (PFI) is an important prognostic factor for progression-free survival. Objective: The aim of the OCEANIA real-world study was to evaluate PFIs across multiple LOTs for Brazilian patients with OC. Methods: OCEANIA, a retrospective, open-cohort study, evaluated treatment patterns and clinical outcomes using a Brazilian private claims database (ORIZON). Patients who had >2 OC-related ICD-10 codes and/or OC-related procedures/treatments were included in the analysis. Patients who had participated in any other clinical trial between 1 January 2010 and 31 December 2019 were excluded. The index date (proxy for diagnosis) was taken as the patient’s first OC-related medical code and/or encounter. LOTs were identified based on drugs dispensed between 2015– 2020. The first LOT was within the initial 30-day period. A gap of 120 days between consecutive dispensation dates defined a change in LOT. Among patients who had progressive disease, PFI was defined as the interval (months) between the last recorded dose of one platinum-based LOT (pLOT) and first dose of the next pLOT, calculated for up to 5 pLOTs. Results: A total of 2529 OC patients were identified, of whom 1441 (57.0%) received antineoplastic therapy. Among these, 87.0% (n=1253) underwent first-line(L) platinum-based chemotherapy. Mean PFI(n;SD) of platinum-based chemotherapy from 1L–2L, 2L–3L, 3L–4L and 4L–5L was 18.7(n=298;11.2), 17.9(n=73;8.0), 14.8(n=20;8.6), and 16.3(n=7;9.6) months, respectively. Conclusion: The OCEANIA study showed a decline in PFI across successive pLOTs in patients with OC from the Brazilian database, likely due to increased resistance to therapies, and/or decreased tolerability, which may limit future treatment options. Therapies that prolong time-to-progression and time-to-next-treatment will help improve outcomes for patients with OC. Funding: Study (213815) and publication funded by GSK. Editorial support by Fishawack Health